We can't find the internet
Attempting to reconnect
14603.1;5 PFLS-LS
Proof-of-Concept: Human FAP-targeting Antibodies as Infarction Prevention Medications
Résumé
Proof-of-Concept: Human FAP-targeting Antibodies as Infarction Prevention Medications
Textes supplémentaires
Abstract
FlowMab is a human monoclonal antibody based medication designed to be administered to high-risk patients to reduce their acute and sub-acute risk of infarction. In this project, FlowMab drug candidates will be generated by Mabimmune for proof-of-concept testing in human biopsies and animal models at the Cardiovascular Research Group, Department of Surgical Research, University Hospital Zurich. This study is anticipated to result in proof-of-concept data of lead candidates necessary for: 1. Securing a partnership with a large industry partner for human clinical trials, 2. Improving FlowMab¿s risk profile for human trials, and 3. cueing the development of a companion diagnostic FAP blood test.
Participants
Simon Philipp Hoerstrup
Kontaktperson
simon_philipp.hoerstrup@chi.usz.ch
Universitätsspital Zürich Simon Philipp Hoerstrup Moussonstrasse 13 8091 Zürich ZH CH
Détails du projet
- Office de recherche
- INNOSUISSE
- Statut du projet
- Abgeschlossen
- Type de projet
- Forschungsprojekt
- Date de début
- 2012-09-30
- Date de fin
- 2015-07-21
- Coûts totaux approuvés
- CHF 295140.00
- Section
- 20 Förderbereich Life Sciences
- Domaine politique NABS
- Nicht aufteilbare / nicht zuteilbare Forschung
Disciplines de recherche
- T115 Medical technology 100.0%